SAP130 and neoplasm: In this process, it will release a large number of soluble cytokines, which will further bind to receptors on inflammatory cells, such as SAP130 and its homologous receptor mincle, so as to trigger the immunosuppressive tumor microenvironment and promote the progress of pancreatic ductal adenocarcinoma [37].